Literature DB >> 11586052

Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.

R Yoshimura1, N Ueda, J Nakamura.   

Abstract

We investigated the relationships between extrapyramidal symptoms (EPS) induced by risperidone, the dosage of risperidone and the combined plasma concentrations of risperidone plus its active metabolite, 9-hydroxyrisperidone, in 20 schizophrenic patients. There was a positive correlation between the scores on the Simpson and Angus Scale and both the dosage of risperidone and the sum of the plasma levels of risperidone and 9-hydroxyrisperidone. These results suggest that EPS induced by risperidone increase in conjunction with both the dosage of risperidone and the total plasma concentrations of the parent compound and its active metabolite. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586052     DOI: 10.1159/000054932

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  10 in total

Review 1.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

2.  Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.

Authors:  Frederik Vandenberghe; Monia Guidi; Eva Choong; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

3.  The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.

Authors:  Nikolina Jovanović; Nada Božina; Mila Lovrić; Vesna Medved; Miro Jakovljević; Alma Mihaljević Peleš
Journal:  Eur J Clin Pharmacol       Date:  2010-06-19       Impact factor: 2.953

4.  Risperidone plasma levels, clinical response and side-effects.

Authors:  Michael Riedel; M J Schwarz; M Strassnig; I Spellmann; A Müller-Arends; K Weber; J Zach; N Müller; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-29       Impact factor: 5.270

5.  Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

Authors:  Norio Yasui-Furukori; Kazuo Mihara; Takenori Takahata; Akihito Suzuki; Taku Nakagami; Ronald De Vries; Tomonori Tateishi; Tsuyoshi Kondo; Sunao Kaneko
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

6.  Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.

Authors:  Michael G Aman; Alexander A Vinks; Bart Remmerie; Erik Mannaert; Yaser Ramadan; Jessica Masty; Ronald L Lindsay; Krista Malone
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

7.  Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents.

Authors:  John J Sheehan; Kristin R Reilly; Dong-Jing Fu; Larry Alphs
Journal:  Innov Clin Neurosci       Date:  2012-07

Review 8.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Pharmacokinetic patterns of risperidone-associated adverse drug reactions.

Authors:  Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen
Journal:  Eur J Clin Pharmacol       Date:  2016-07-04       Impact factor: 2.953

10.  Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients.

Authors:  Akira Suda; Saki Hattori; Ikuko Kishida; Masatoshi Miyauchi; Yohko Shiraishi; Mami Fujibayashi; Natsuki Tsujita; Chie Ishii; Norio Ishii; Toshio Moritani; Yoshio Hirayasu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-09-17       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.